Project Grant R56HL169267
Award Date
9/26/24
Completion Date
8/31/25
Dollars Obligated
$678K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $751,747 project grant under CFDA 93.837, Cardiovascular Diseases Research, to the University of North Carolina at Chapel Hill. The grant, titled "CARM1-Mediated Transcriptional and Posttranscriptional Regulation of Cardiomyocyte Maturation," will fund research to define key factors and signaling pathways that regulate the maturation of cardiomyocytes, the primary cells responsible for cardiac contraction. The project aims...
This Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the underlying causes of why pluripotent-derived cardiomyocytes (PSC-CMs) fail to fully mature. The $2,249,307 award, provided to The Johns Hopkins University from September 1, 2024 to May 31, 2028, aims to leverage a comprehensive computational approach to identify a conserved gene regulatory network that underlies the...
This federal Project Grant award of $107,298 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to determine the mechanisms underlying the specific regulation of cardiac cardiolipin, a phospholipid crucial for mitochondrial energy production in the heart. The research aims to: 1) evaluate the significance and preference of linoleic acid-cardiolipin in cardiac energy production; 2) characterize the...
The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $785,198 to the Albert Einstein College of Medicine to study the role of chaperone-mediated autophagy (CMA) in regulating the function and phenotypic transitions of cardiac fibroblasts and myofibroblasts following myocardial infarction. The research aims to determine how CMA modulates the proteomic profile, phenotype, and function of reparative fibroblasts and...
The University of Arizona was awarded a $625,316 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the role of RNA methylation and translational regulation in the oxidative stress response of heart failure. The research aims to elucidate how the YTHDF2 protein binds to methylated NRF2 mRNA to selectively induce its translation under oxidative stress, a process that may be impaired in end-stage heart failure. The...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
This $653,854 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The purpose of the grant is to study the impact of cardiomyocyte-selective modulation of natriuretic peptide signaling pathways on cardiomyopathy progression and ventricular arrhythmia susceptibility in preclinical models. The specific aims are to: 1) Define how cardiomyocyte-specific modulation of PKG1 activity modifies cardiomyopathy...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $439,065 to Swarthmore College to conduct research on the signal-dependent regulation of cardiac progenitor proliferation. The goal is to decipher how signaling pathways coordinate cardiomyocyte lineage division dynamics during prenatal growth, which is essential for diagnosing and treating congenital heart disorders. The research leverages the cellular simplicity...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $156,600 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Texas Southwestern Medical Center (UT Southwestern). The 5-year grant will support research to define the role of the PHF7 protein in driving cardiac reprogramming and improving heart function following a myocardial infarction. Specifically, the project aims to: 1) Characterize...